Starphama has paused sales of its antiviral COVID-19 nasal spray following correspondence with the UK medicines regulator “in relation to specific promotional claims made for Viraleze, including references to SARS-CoV-2 and COVID-19, and the interrelationship between these product claims and its categorization,” according to the firm.
Australia’s Starpharma has paused UK sales of its Viraleze antiviral COVID-19 nasal spray following an intervention by the country’s medicines regulator, the MHRA.
According to the firm, the MHRA contacted Starpharma’s UK retail partner McKesson – which operates the LloydsPharmacy chain – “in...